Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$19.30
+0.07 (+0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $115.8M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.7B
P/E
68.9x
↑EV/EBITDA
14.0x
↑ROE
3.8%
↑Gross Margin
37.1%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.7%
FCF CAGR
—
FCF margin
3.8%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.06B · net income $139.7M · FCF $115.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.06B | $3.06B | $2.63B | $2.53B | $2.67B |
| Net Income | $139.7M | $139.7M | $55.9M | $27.4M | $-118.9M |
| EBITDA | $559.8M | $559.8M | $466.5M | $427.0M | $178.3M |
| EPS | 0.41 | 0.41 | 0.16 | 0.08 | -0.34 |
| Gross Margin | 37.1% | 37.1% | 34.7% | 39.2% | 25.8% |
| Operating Margin | 9.9% | 9.9% | 6.4% | 12.5% | 1.5% |
| Net Margin | 4.6% | 4.6% | 2.1% | 1.1% | -4.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.49 | 0.49 | 0.52 | 0.52 | 0.37 |
| Current Ratio | 1.19 | 1.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $115.8M | $115.8M | $175.7M | $-360.7M | $-575.7M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 1.6% | 0.8% | -3.4% |
| Valuation | |||||
| P/E | 68.93 | 68.93 | 103.38 | 254.25 | — |
| EV/EBITDA | 14.00 | 14.00 | 15.06 | 19.51 | 51.69 |
| P/B | 1.81 | 1.81 | 1.65 | 1.99 | 2.40 |
| Growth & Yield | |||||
| Revenue Growth | 16.4% | 16.4% | 4.1% | -5.2% | — |
| EPS Growth | 156.2% | 156.2% | 100.0% | 123.5% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
61.0%
EPS terminal req.
$1.71
Spread vs growth
95.2%
5Y implied EPS CAGR
38.3%
EPS terminal req.
$2.07
Spread vs growth
118.0%
10Y implied EPS CAGR
23.3%
EPS terminal req.
$3.34
Spread vs growth
132.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.6%
Start / end P/E
133.7x → 47.1x
EPS bridge
0.16 → 0.41
Residual
-101.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.